[go: up one dir, main page]

WO2009069002A3 - Low dose colony stimulating factors to treat amyloidosis - Google Patents

Low dose colony stimulating factors to treat amyloidosis Download PDF

Info

Publication number
WO2009069002A3
WO2009069002A3 PCT/IB2008/003879 IB2008003879W WO2009069002A3 WO 2009069002 A3 WO2009069002 A3 WO 2009069002A3 IB 2008003879 W IB2008003879 W IB 2008003879W WO 2009069002 A3 WO2009069002 A3 WO 2009069002A3
Authority
WO
WIPO (PCT)
Prior art keywords
colony stimulating
low dose
stimulating factor
tissue
stimulating factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/003879
Other languages
French (fr)
Other versions
WO2009069002A2 (en
Inventor
Serge Rivest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Publication of WO2009069002A2 publication Critical patent/WO2009069002A2/en
Anticipated expiration legal-status Critical
Publication of WO2009069002A3 publication Critical patent/WO2009069002A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by administration of a low dose of colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by administration of a low dose of colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis.
PCT/IB2008/003879 2007-11-29 2008-12-01 Low dose colony stimulating factors to treat amyloidosis Ceased WO2009069002A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99115907P 2007-11-29 2007-11-29
US60/991,159 2007-11-29

Publications (2)

Publication Number Publication Date
WO2009069002A2 WO2009069002A2 (en) 2009-06-04
WO2009069002A3 true WO2009069002A3 (en) 2011-04-28

Family

ID=40679070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/003879 Ceased WO2009069002A2 (en) 2007-11-29 2008-12-01 Low dose colony stimulating factors to treat amyloidosis

Country Status (1)

Country Link
WO (1) WO2009069002A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946309A1 (en) * 2019-04-03 2022-02-09 Oncopeptides AB Treatment of al amyloidosis with melflufen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060610A2 (en) * 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060610A2 (en) * 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWATA, T. ET AL.: "Amyloid b Protein Deposition in Osteopetrotic (oplop) Mice is Reduced by Injections of Macrophage Colony Stimulating Factor.", THE JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol. 33, no. 6, 1 November 2005 (2005-11-01), pages 654 - 660 *
MITRASINOVIC, O. M. ET AL.: "Microglial Overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta", NEUROSCIENCE LETTERS, vol. 344, no. 6, 3 July 2003 (2003-07-03), pages 185 - 188 *

Also Published As

Publication number Publication date
WO2009069002A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2008060610A3 (en) Systemic administration of colony stimulating factors to treat amyloid associated disorders
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2008073670A3 (en) Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
WO2007143231A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
WO2006119300A3 (en) Method of using oxidative reductive potential water solution in dental applications
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
WO2007089611A3 (en) Compositions and their uses directed to huntingtin
WO2009050506A3 (en) Combination 059
MY151018A (en) Use of nutritional compositions for preventing disorders
EP2298862A3 (en) Mesenchymal stem cells and uses therefor
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008150490A3 (en) Uses and compositions for treatment of psoriasis and crohn's disease
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
BRPI0712322A2 (en) compounds and combinations thereof for inhibiting beta-amyloid production and methods of using them
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
ATE457722T1 (en) IMPROVED CELL THERAPY AND TISSUE REGENERATION USING SHOCK WAVES IN PATIENTS WITH CARDIOVASCULAR AND NEUROLOGICAL DISEASES
TW200719882A (en) Treatment of connective tissue diseases of the skin
ATE553760T1 (en) USE OF ALVERINE TO TREAT SKIN DISEASES
NO20071704L (en) Prostaglandin derivatives for the treatment of gastrointestinal disorder
WO2009069002A3 (en) Low dose colony stimulating factors to treat amyloidosis
EP2316941A3 (en) Compositions and their uses directed to IL-4R alpha
EP1628663A4 (en) Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08855445

Country of ref document: EP

Kind code of ref document: A2